Resumen de Investigación
Analyzed using Evidence Intelligence™

Cloud platform improves algorithm testing for type 1 diabetes

Última actualización 18 de julio de 2026

Key finding

Time spent in target range increased from 51% to 52%.

This study evaluated a cloud-based platform for developing algorithms for type 1 diabetes using various artificial pancreas systems. It found slight improvements in glucose management metrics.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study evaluated a cloud-based platform for developing algorithms for type 1 diabetes using various artificial pancreas systems. It found slight improvements in glucose management metrics.

Clinical relevance

These findings are significant as they suggest that while new technologies like artificial pancreas systems may offer some benefits in managing blood glucose levels, the overall impact on hypoglycemia remains uncertain. This highlights the need for further research to fully understand the effectiveness of these interventions in real-world settings.

Keep in mind

The study design was non-randomized, which may introduce bias. The sample size and demographic details were not specified. Effectiveness of interventions remains unclear due to lack of statistical significance.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Mohamed RS, Remi R, Ahmad H, Othmar M. A cloud-based platform for developing and testing algorithms for type 1 diabetes. PLOS ONE. 2020;15(12):e0243139. doi:10.1371/journal.pone.0243139

Efectos Principales

Time spent at glucose levels in target range increased from 51% to 52%.

Mean glucose decreased from 7.9 to 7.8 mmol/L.

Time spent at glucose levels in target range increased from 62% to 63%.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Hybrid closed-loop system, Insulin therapy and Hypoglycemia events, Mean glucose from rtCGM, Time in range.

Primary intervention

Hybrid closed-loop system

Primary outcomes

  • Hypoglycemia events
  • Mean glucose from rtCGM
  • Time in range

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

4

Related topics

6

Evidence pairs

498

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 6 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

Insulin Delivery Systems and CGM Time in Range

Evidencia relacionada

Relación de evidencia

Insulin Therapies and CGM Time in Range

Guardar evidencia

Relación de evidencia

Insulin Delivery Systems and Hypoglycemia

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Hypoglycemia events

Hybrid closed-loop system → Hypoglycemia events

Hybrid closed-loop system → Hypoglycemia events

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 3 studies
ImpactScore™
50
Neutral
ConsistencyScore™
67
generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence Tracker

Mean glucose from rtCGM

Hybrid closed-loop system → Mean glucose from rtCGM

Hybrid closed-loop system → Mean glucose from rtCGM

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time in range

Hybrid closed-loop system → Time in range

Hybrid closed-loop system → Time in range

Evidence Intelligence™
EvidenceScore™
84
Strong
ImpactScore™
79
Positive
ConsistencyScore™
80
consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence Tracker

Hypoglycemia events

Insulin therapy → Hypoglycemia events

Insulin therapy → Hypoglycemia events

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Mean glucose from rtCGM

Insulin therapy → Mean glucose from rtCGM

Insulin therapy → Mean glucose from rtCGM

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Time in range

Insulin therapy → Time in range

Insulin therapy → Time in range

Evidence Intelligence™
EvidenceScore™
77
Strong
ImpactScore™
67
Slightly Positive
ConsistencyScore™
67
generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Time in target glucose range improved by 1%.
  • Mean glucose levels decreased by 1 mmol/L.
  • No change in the number of hypoglycemic events.
who this applies

A quién se aplica

  • Individuals with type 1 diabetes.
  • Participants using insulin delivery systems.
keep in mind

Tener en Cuenta

  • The findings may not be generalizable to all populations.
  • Further research is needed to confirm the effectiveness of the interventions.
  • The study did not assess long-term outcomes or quality of life.
between the lines

Entre Líneas

  • The study design was non-randomized, which may introduce bias.
  • The sample size and demographic details were not specified.
  • Effectiveness of interventions remains unclear due to lack of statistical significance.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and Hypoglycemia.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Delivery Systems improve cgm time in range?

Strong Evidence

Insulin Delivery Systems may improve CGM Time in Range.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Time in range

    EvidenceScore™ Strong | EvidenceScore™ 83.6 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
15 supporting studiesUpdated: Jul 2026

Does Insulin Therapies improve cgm time in range?

Strong Evidence

Insulin Therapies may improve CGM Time in Range.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Time in range

    EvidenceScore™ Strong | EvidenceScore™ 77.4 | weak positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
9 supporting studiesUpdated: Jul 2026

Does Insulin Delivery Systems affect hypoglycemia?

Strong Evidence

Current evidence does not show a clear benefit of Insulin Delivery Systems for Hypoglycemia.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Hypoglycemia events

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | neutral | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 5 supporting studies and existing graph evidence signals.

Limitations

  • Population details are unavailable.
5 supporting studiesUpdated: Jul 2026

Does Insulin Delivery Systems improve mean glucose levels?

Strong Evidence

Insulin Delivery Systems may improve Mean Glucose Levels.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    Mean glucose from rtCGM

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
6 supporting studiesUpdated: Jul 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.